Clinical Coagulation, Malmö
541 – 550 of 659
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Pharmacokinetic studies on Wilfactin((R)), a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
- Contribution to journal › Article
-
Mark
Risk factors for venous thrombosis in Swedish children and adolescents.
- Contribution to journal › Article
-
Mark
Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo.
- Contribution to journal › Article
-
Mark
Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee.
- Contribution to journal › Article
-
Mark
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
- Contribution to journal › Article
-
Mark
Protein Z and protein Z-dependent protease inhibitor - Determinants of levels and risk of venous thrombosis
- Contribution to journal › Article
- 2004
-
Mark
Co-segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1.
- Contribution to journal › Article
-
Mark
Hereditary thrombophilia and fetal loss: a prospective follow-up study
- Contribution to journal › Article
-
Mark
Economic evaluation: what are we looking for and how do we get there?
- Contribution to journal › Article
-
Mark
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study
- Contribution to journal › Article
